This dosage information may not include all the information needed to use Mesalamine safely and effectively. See additional information for Mesalamine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Ulcerative Colitis - Active
Asacol(R), Delzicol(TM): 800 mg orally 3 times a day
Asacol(R) HD: 1600 mg orally 3 times a day
Lialda(R): 2.4 to 4.8 g orally once a day
Pentasa(R): 1 g orally 4 times a day
Duration of therapy:
-Asacol(R), Asacol(R) HD, Delzicol(TM): 6 weeks
-Lialda(R), Pentasa(R): Up to 8 weeks in controlled trials
-Asacol(R) HD: Safety and efficacy have not been established beyond 6 weeks.
-Asacol(R), Delzicol(TM): Treatment of mildly to moderately active ulcerative colitis
-Asacol(R) HD: Treatment of moderately active ulcerative colitis
-Lialda(R): Induction of remission of active mild to moderate ulcerative colitis
-Pentasa(R): Induction of remission and treatment of mildly to moderately active ulcerative colitis
Rectal suspension enema: 4 g rectally once a day at bedtime
Duration of therapy: Generally from 3 to 6 weeks, depending on symptoms and sigmoidoscopic findings; effect may be seen within 3 to 21 days
-Best results are achieved if used soon after the bowel is emptied.
-Rectal suspension enemas should be retained for approximately 8 hours.
Approved indications: Treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis, or proctitis
Usual Adult Dose for Ulcerative Colitis - Maintenance
Apriso(R): 1.5 g orally once a day in the morning
Asacol(R), Delzicol(TM): 1.6 g orally per day in divided doses
Lialda(R): 2.4 g orally once a day
Pentasa(R): 1 g orally 4 times a day
Approved indication: Maintenance of remission of ulcerative colitis; Pentasa(R) has not been explicitly approved for this indication.
Usual Adult Dose for Ulcerative Proctitis
Rectal suppository: 1 g rectally once a day at bedtime
Duration of therapy: Generally from 3 to 6 weeks, depending on symptoms and sigmoidoscopic findings
-Rectal suppositories should be retained for 1 to 3 hours or longer, if possible.
-Safety and efficacy have not been established beyond 6 weeks.
Approved indication: For the treatment of mild to moderately active ulcerative proctitis
Renal Dose Adjustments
Patients with known renal dysfunction or history of renal disease: Caution recommended.
Liver Dose Adjustments
Patients with liver dysfunction/disease: Caution recommended.
Consult WARNINGS section for dosing related precautions.
Safety and efficacy have not been established in pediatric patients (less than 18 years of age).
Data not available
-Apriso(R): Capsules may be taken without regard to meals; should not be coadministered with antacids (coating of granules depends on pH for dissolution).
-Asacol(R), Asacol(R) HD, Delzicol(R): Tablets/capsules should be swallowed whole without cutting, breaking, or chewing (coating is important part of delayed-release formulation).
-Asacol(R) HD: Tablets may be taken without regard to meals.
-Delzicol(R): Capsules should be taken at least 1 hour before or 2 hours after a meal.
-Lialda(R): Tablets should be taken with a meal; should be swallowed whole, keeping the outer coating intact.
-Rectal suppositories: If a dose is missed, it should be administered as soon as possible, unless it is almost time for the next dose; patients should not use 2 suppositories to make up for a missed dose.
-Rectal suspension enemas: The manufacturer's product information should be consulted.
-Asacol(R) HD, Delzicol(R): Protect from moisture; close container tightly and keep desiccant in bottle.
-Rectal suppositories: Store below 25 degrees Celsius (77 degrees Fahrenheit), may refrigerate. Keep away from direct heat, light, or humidity.
-Apriso(R) capsules contain aspartame; usual adult dose provides equivalent of 2.24 mg of phenylalanine per day.
-Asacol(R), Asacol(R) HD, Delzicol(TM), Lialda(R): The release of mesalamine in the colon may be delayed in patients with pyloric stenosis or other organic or functional obstruction in the upper gastrointestinal tract due to prolonged gastric retention of mesalamine tablets/capsules.
-One Asacol(R) HD 800 mg tablet is not bioequivalent to two Asacol(R) 400 mg tablets or to two Delzicol(TM) 400 mg capsules.
-Asacol(R), Asacol(R) HD, Delzicol(TM): Intact, partially intact, and/or tablet/capsule shells reported in the stool; patients should contact physician if this occurs repeatedly.
-Rectal suppositories and rectal suspension enemas cause staining of direct contact surfaces (including fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel).
-Gastrointestinal: Patients should be observed closely for worsening of colitis symptoms during therapy.
-Hematologic: Blood cell counts should be monitored closely in elderly patients during therapy.
-Renal: Renal function should be evaluated in all patients prior to initiation of and periodically during therapy.
More about mesalamine
- Mesalamine controlled-release capsules
- Mesalamine delayed-release capsules
- Mesalamine delayed-release tablets
- Mesalamine enema
- Mesalamine extended-release capsules
- More (5) »